Capital Investment Advisory Services LLC trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,588 shares of the pharmaceutical company’s stock after selling 675 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $850,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after buying an additional 75 shares during the period. Buckingham Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 3.6% in the second quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock worth $292,000 after buying an additional 79 shares during the period. Eqis Capital Management Inc. raised its holdings in shares of Vertex Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 14,549 shares of the pharmaceutical company’s stock worth $1,875,000 after buying an additional 83 shares during the period. Grandfield & Dodd LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.6% in the second quarter. Grandfield & Dodd LLC now owns 5,805 shares of the pharmaceutical company’s stock worth $748,000 after buying an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System raised its holdings in shares of Vertex Pharmaceuticals by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 15,400 shares of the pharmaceutical company’s stock worth $1,985,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 93.36% of the company’s stock.

In other news, EVP Stuart A. Arbuckle sold 6,290 shares of the business’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $143.97, for a total value of $905,571.30. Following the completion of the sale, the executive vice president now owns 116,952 shares of the company’s stock, valued at approximately $16,837,579.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul M. Silva sold 1,289 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $152.88, for a total transaction of $197,062.32. Following the completion of the sale, the senior vice president now directly owns 17,923 shares of the company’s stock, valued at approximately $2,740,068.24. The disclosure for this sale can be found here. Insiders sold a total of 198,030 shares of company stock valued at $28,878,352 in the last three months. Insiders own 1.80% of the company’s stock.

Several brokerages have recently weighed in on VRTX. Royal Bank Of Canada reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Robert W. Baird reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. HC Wainwright reiterated a “hold” rating and issued a $85.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Finally, Maxim Group reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $173.15.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up $5.07 during trading on Friday, hitting $149.97. The stock had a trading volume of 1,880,000 shares, compared to its average volume of 1,720,000. The firm has a market cap of $37,930.00, a PE ratio of 241.50, a price-to-earnings-growth ratio of 3.68 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 4.56.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s revenue was up 39.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 EPS. equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Stake Decreased by Capital Investment Advisory Services LLC” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-stake-decreased-by-capital-investment-advisory-services-llc/1678500.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.